Cargando…
Clinical and Economic Benefits of Lenzilumab Plus Standard of Care Compared with Standard of Care Alone for the Treatment of Hospitalized Patients with Coronavirus Disease 19 (COVID-19) from the Perspective of National Health Service England
PURPOSE: To estimate the clinical and economic benefits of lenzilumab plus standard of care (SOC) compared with SOC alone in the treatment of hospitalized COVID-19 patients from the National Health Service (NHS) England perspective. METHODS: A cost calculator was developed to estimate the clinical b...
Autores principales: | Kilcoyne, Adrian, Jordan, Edward, Thomas, Kimberly, Pepper, Alicia N, Zhou, Allen, Chappell, Dale, Amarapala, Miyuru, Thériault, Rachel-Karson, Thompson, Melissa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014956/ https://www.ncbi.nlm.nih.gov/pubmed/35444434 http://dx.doi.org/10.2147/CEOR.S360741 |
Ejemplares similares
-
1134. Lenzilumab Treatment in COVID-19 Pneumonia Reduces Circulating Cytokines and Markers of Systemic Inflammation
por: Chappell, Dale, et al.
Publicado: (2022) -
C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 ‘LIVE-AIR’ trial
por: Temesgen, Zelalem, et al.
Publicado: (2023) -
Hydroxychloroquine plus standard of care compared with standard of care alone in COVID-19: a meta-analysis of randomized controlled trials
por: Amani, Bahman, et al.
Publicado: (2021) -
GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study
por: Temesgen, Zelalem, et al.
Publicado: (2020) -
Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019
por: Aroldi, Andrea, et al.
Publicado: (2021)